贝前列素钠对急性ST段抬高型心肌梗死患者预后的影响

Effect of beraprost Sodium on Prognosis of Patients with Acute ST Elevation Myocardial Infarction

贺俊波 ¹刘峰 ¹刘华东¹

扫码查看

作者信息

1. 深圳市人民医院暨南大学第二临床医学院南方科技大学第一附属医院心血管内科深圳市心血管微创医学工程技术研究开发中心,广东深圳 518020
折叠

摘要

目的:评估贝前列素钠对急性ST段抬高型心肌梗死(STEMI)患者预后的影响.方法:随机选取 2019 年 8 月～2021 年 12 月深圳市人民医院收治的STEMI患者 90 例为研究对象,随机分为贝前列素钠组与对照组各 45 例.比较两组术后 1 个月内、12 个月内的主要不良事件(MACE)、靶血管血运重建、心源性死亡发生情况.结果:术后 1 个月内MACE、靶血管血运重建、心源性死亡发生率,术后 12 个月内心源性死亡发生率比较,差异有统计学意义(P<0.05).术后 12 个月内MACE、靶血管血运重建比较差异无统计学意义(P>0.05).结论:贝前列素钠能降低术后 1 个月内MACE、靶血管血运重建及心源性死亡发生率,降低术后 12 个月内心源性死亡发生率.

Abstract

Objective To evaluate the effect of beraprost sodium on the prognosis of patients with acute ST segment elevation myo-cardial infarction(STEMI).Method 90 patients with STEMI who were treated in Shenzhen People's Hospital from August 2019 to De-cember 2021 were randomly selected as research object.They were randomly divided into:45 patients in the beraprost sodium group;45 cases in the control group.Compare the main adverse events(MACE),target vessel revascularization,and incidence of cardiac death within 1 month and 12 months after surgery in each group.Results The incidence of MACE,target vessel revascularization,and cardi-ac death within one month after surgery,as well as the incidence of cardiac death at 12 months after surgery,were statistically signifi-cant(P<0.05).There was no statistically significant difference in MACE and target vessel revascularization within 12 months after surgery(P>0.05).Conclusion Beraprost sodium can reduce the incidence of MACE,target vessel revascularization and cardiac death within one month after operation,and reduce the incidence of cardiac death within 12 months after operation.

关键词

贝前列素钠/急性ST段抬高型心肌梗死/预后

Key words

Beraprost sodium/Acute ST segment elevation myocardial infarction/Prognosis

引用本文复制引用

出版年

2024

吉林医学

吉林省人民医院

吉林医学

影响因子：0.926

ISSN：1004-0412

段落导航